During the last session, Fennec Pharmaceuticals Inc (NASDAQ:FENC)’s traded shares were 0.37 million, with the beta value of the company hitting 0.26. At the end of the trading day, the stock’s price was $5.32, reflecting an intraday gain of 12.71% or $0.6. The 52-week high for the FENC share is $11.92, that puts it down -124.06 from that peak though still a striking 25.56% gain since the share price plummeted to a 52-week low of $3.96. The company’s market capitalization is $203.73M, and the average intraday trading volume over the past 10 days was 0.15 million shares, and the average trade volume was 95.45K shares over the past three months.
Fennec Pharmaceuticals Inc (FENC) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. FENC has a Sell rating from 0 analyst(s) out of 12 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 11 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.1.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Fennec Pharmaceuticals Inc (NASDAQ:FENC) trade information
Fennec Pharmaceuticals Inc (FENC) registered a 12.71% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 12.71% in intraday trading to $5.32, hitting a weekly high. The stock’s 5-day price performance is 33.33%, and it has moved by 16.16% in 30 days. Based on these gigs, the overall price performance for the year is -39.75%. The short interest in Fennec Pharmaceuticals Inc (NASDAQ:FENC) is 1.78 million shares and it means that shorts have 23.6 day(s) to cover.
The consensus price target of analysts on Wall Street is $16, which implies an increase of 66.75% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12 and $19 respectively. As a result, FENC is trading at a discount of -257.14% off the target high and -125.56% off the low.
Fennec Pharmaceuticals Inc (FENC) estimates and forecasts
Statistics show that Fennec Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. Fennec Pharmaceuticals Inc (FENC) shares have gone down -20.60% during the last six months, with a year-to-date growth rate more than the industry average at 113.33% against 17.90. In the rating firms’ projections, revenue will increase 124.19% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 8.01M as predicted by 4 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 8.42M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 9.73M and 25.38M respectively. In this case, analysts expect current quarter sales to shrink by -17.73% and then drop by -66.82% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -2.95%. While earnings are projected to return 94.67% in 2024.
FENC Dividends
Fennec Pharmaceuticals Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Fennec Pharmaceuticals Inc (NASDAQ:FENC)’s Major holders
Fennec Pharmaceuticals Inc insiders own 16.22% of total outstanding shares while institutional holders control 54.73%, with the float percentage being 65.32%. SOUTHPOINT CAPITAL ADVISORS LP is the largest shareholder of the company, while 94.0 institutions own stock in it. As of 2024-06-30, the company held over 4.08 million shares (or 15.0757% of all shares), a total value of $24.91 million in shares.
The next largest institutional holding, with 2.41 million shares, is of SONIC GP LLC’s that is approximately 8.9013% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $14.71 million.
Also, the Mutual Funds coming in first place with the largest holdings of Fennec Pharmaceuticals Inc (FENC) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Jun 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 876.21 shares. This amounts to just over 3.19 percent of the company’s overall shares, with a $4.66 million market value. The same data shows that the other fund manager holds slightly less at 565.49, or about 2.06% of the stock, which is worth about $3.01 million.
